Spinal muscular atrophy (SMA) is a genetic neuromuscular disease that attacks the motor neurons associated with muscles used for activities like crawling, walking, head and neck control, and swallowing. Gene therapy is emerging as a promising approach to treat SMA by delivering a functional copy of the SMN1 gene to produce more SMN protein.
The global Spinal Muscular Atrophy Market is estimated to be valued at US$ 2089.13 Bn in 2024 and is expected to exhibit a ... Read more
